- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02511860
Burdock and Blood Pressure in African-American Women
July 29, 2015 updated by: Proactive Health Labs
Burdock and Blood Pressure in African-American Women: A Randomized Controlled Trial
This is a study of women aged 18-65, to determine the physiological effects of consuming burdock root in supplement form.
Burdock has long been used by herbalists for its diuretic and blood sugar lowering properties.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
This study will allow us to determine the effect of burdock consumption on basic laboratory tests such as the complete metabolic panel (CMP) as well as the effect on blood pressure over time.
Participants will self-monitor their blood pressures and undergo lab testing.
They will also complete symptom inventories to determine subjective factors that change with burdock consumption, such as menstrual water retention.
Subjects will undergo electronic body composition testing before and after the intervention.
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Dr De
- Phone Number: 2 3108995577
- Email: mde@phlabs.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Must be able to swallow tablets
- African-American race
- Able to travel to our clinic in Santa Monica
Exclusion Criteria:
- Severely low blood pressure
- Hypoglycemia
- Baseline creatinine over 1.2
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Patients will consume a placebo pill containing methylcellulose.
|
Methylcellulose (inert) tablet taken as placebo
|
Active Comparator: Active
Patients will consume 850 mg of burdock twice per day.
|
Subjects will consume burdock daily and will undergo laboratory tests to determine the effect of burdock, if any, on organ function.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Blood pressure
Time Frame: 6 weeks
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Body fat percentage
Time Frame: 6 Weeks
|
6 Weeks
|
Extracellular/Total Body Water Ratio
Time Frame: 6 Weeks
|
6 Weeks
|
Hemoglobin A1c
Time Frame: 6 weeks
|
6 weeks
|
Blood urea nitrogen
Time Frame: 6 weeks
|
6 weeks
|
Creatinine
Time Frame: 6 weeks
|
6 weeks
|
Fasting Blood Glucose
Time Frame: 6 weeks
|
6 weeks
|
Liver function tests
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Dr. De, Proactive Health Labs
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2015
Primary Completion (Anticipated)
November 1, 2015
Study Completion (Anticipated)
February 1, 2016
Study Registration Dates
First Submitted
July 15, 2015
First Submitted That Met QC Criteria
July 29, 2015
First Posted (Estimate)
July 30, 2015
Study Record Updates
Last Update Posted (Estimate)
July 30, 2015
Last Update Submitted That Met QC Criteria
July 29, 2015
Last Verified
July 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 00000001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States